2.3 Special Donations

Special Donations

Quick Answer: Special donations depart from routine allogeneic ("for anyone") collection in who the unit is intended for and, sometimes, in the eligibility criteria applied. Autologous donation is collected for the donor's own later use and permits relaxed criteria; directed donation is collected for a specific named recipient but must still meet full allogeneic standards; therapeutic phlebotomy is collected to treat the donor-patient's own condition and may only join the general supply if the donor also independently qualifies as a standard allogeneic donor; and granulocyte donation is a specialized apheresis collection requiring donor stimulation.

Autologous Donation

Autologous donation means the donor and the intended recipient are the same person. This category covers several distinct collection methods:

• Preoperative autologous donation (PAD): the patient donates one or more units in advance of a scheduled surgery likely to require transfusion, for use during or after that surgery
• Acute normovolemic hemodilution: blood is withdrawn from the patient immediately before or at the start of surgery, replaced with crystalloid/colloid to maintain blood volume, and the withdrawn whole blood is returned to the patient later in the case (often after the highest-blood-loss portion of surgery is complete), so the blood lost during surgery has a lower red cell concentration
• Intraoperative and postoperative blood salvage ("cell saver"): blood lost into the surgical field or a drain is collected, washed, and returned to the patient during or shortly after the procedure

Because the intended recipient is the donor, PAD eligibility criteria are relaxed relative to allogeneic standards — for example, a lower minimum hemoglobin threshold is commonly used, and some conditions that would defer an allogeneic donor (certain infections, for instance) do not automatically disqualify a patient from donating for their own use, since the recipient already carries that risk. However, infectious disease testing is still generally performed on autologous units, both to protect staff handling the unit and because an unused autologous unit could potentially be considered for crossover into the general supply under strict, defined circumstances (which requires the unit to independently meet allogeneic standards, including full testing and eligibility — it is not automatically eligible just because it went untested initially).

Autologous units must be clearly and distinctly labeled (commonly "For Autologous Use Only") and are typically restricted to a defined minimum time before surgery (for example, not within roughly 72 hours of the scheduled procedure, to avoid the patient being anemic or hemodynamically compromised going into surgery) and expire under the same dating rules as standard units of the same type.

Directed and Dedicated Donation

Directed donation occurs when a specific donor is recruited by the patient or family for a specific recipient — a common scenario for pediatric patients, obstetric patients anticipating transfusion needs, or patients who prefer a known donor for personal reasons. The critical exam point: a directed donor must meet every allogeneic eligibility and testing requirement, with no relaxation, because if the intended recipient does not end up needing the unit (or declines it), the unit may be released into the general allogeneic supply. There is no special eligibility exemption simply because the donor was chosen by the family.

"Dedicated donation" is sometimes used interchangeably with directed donation in casual usage, but in more precise usage it can refer to a donor recruited to donate repeatedly for a specific recipient with an ongoing need (for example, a patient with a rare antigen phenotype requiring antigen-matched units on a recurring basis); the eligibility standard remains full allogeneic criteria in either case.

The Irradiation Rule for Related Donors

A specialist-level detail that is frequently tested: when a directed unit comes from a blood relative of the recipient (particularly relevant for intrauterine transfusion, neonatal/pediatric exchange or intrauterine transfusion, or any immunocompromised recipient), the unit must be irradiated before transfusion, regardless of whether it would otherwise be irradiated for that recipient's clinical indication alone. The rationale: biological relatives are more likely to share HLA haplotypes with the recipient, which increases the risk that viable donor T-lymphocytes in the unit will not be recognized as foreign by the recipient's immune system, engraft, and cause transfusion-associated graft-versus-host disease (TA-GVHD) — a rare but often fatal complication. Irradiation inactivates donor lymphocytes' ability to proliferate while leaving red cells and platelets functional, preventing this outcome.

Therapeutic Phlebotomy

Therapeutic phlebotomy is performed as a treatment for the donor's own medical condition, not primarily to supply blood for transfusion. Common indications include hereditary hemochromatosis (removing iron-loaded red cells to reduce total body iron burden), polycythemia vera and other conditions causing pathologic erythrocytosis, and porphyria cutanea tarda (where reducing iron stores improves the underlying metabolic derangement).

The key specialist-level distinction: whether a therapeutic phlebotomy unit may enter the general allogeneic supply depends entirely on whether the donor-patient also independently satisfies every standard allogeneic donor eligibility criterion (history, vital signs, hemoglobin, testing, no disqualifying deferrals) — the underlying medical condition prompting the phlebotomy is not itself automatically disqualifying (hereditary hemochromatosis, for example, does not make red cells unsafe for transfusion), but it is also not a basis for exemption from any other standard requirement. If the donor-patient does not meet full allogeneic criteria, the unit is discarded as medical waste rather than transfused to anyone, even though the phlebotomy itself was medically necessary for the patient.

Granulocyte and Other Specialized Apheresis Collections

Granulocyte donation supports patients with severe, prolonged neutropenia (often during intensive chemotherapy or after hematopoietic stem cell transplantation) who have a documented infection not responding to antimicrobial therapy alone. Because circulating granulocyte counts in a healthy donor are normally too low to yield a clinically useful dose through apheresis alone, donors are typically pretreated with a stimulating agent — commonly a corticosteroid, a growth factor such as G-CSF, or both — in the day(s) before collection to mobilize granulocytes from the bone marrow into circulation. This mobilization step introduces donor-safety considerations (medication side effects, a more involved consent process) beyond those of routine plasma or platelet apheresis, and granulocyte products also have unique handling requirements (they are not irradiated in the same manner as other cellular products for storage, are stored at room temperature, and have a very short dating period, often required to be transfused within 24 hours of collection).

Putting It Together for the Exam

When a vignette describes a special donation, first ask: who is the intended recipient, and why is the unit being collected? If the donor is the future recipient, think autologous and relaxed criteria. If a specific other person is the intended recipient but the donor is otherwise a member of the general public, think directed donation with full allogeneic standards, and check whether the donor is a blood relative (irradiation trigger). If the reason for collection is a medical condition of the donor unrelated to supplying the blood bank, think therapeutic phlebotomy, and the question is really testing whether you know the unit can only be released for transfusion if the donor independently clears every standard allogeneic requirement.